CIAN Agro Industries & Infrastructure Limited (BOM:519477)
India · Delayed Price · Currency is INR 429.60
+6.50 (1.54%)
At close: Aug 4, 2025
Marinus Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 10,290 | 1,707 | 2,900 | 2,542 | 2,655 | Upgrade |
Other Revenue | - | - | -0 | - | - | Upgrade |
| 10,290 | 1,707 | 2,900 | 2,542 | 2,655 | Upgrade | |
Revenue Growth (YoY) | 502.78% | -41.13% | 14.07% | -4.24% | 25.15% | Upgrade |
Cost of Revenue | 7,030 | 1,329 | 2,405 | 2,065 | 2,244 | Upgrade |
Gross Profit | 3,260 | 377.79 | 495.38 | 477.55 | 410.89 | Upgrade |
Selling, General & Admin | 331.36 | 65.9 | 60.48 | 64.36 | 54.77 | Upgrade |
Other Operating Expenses | 1,507 | 120.35 | 180.06 | 174.62 | 120.86 | Upgrade |
Operating Expenses | 2,309 | 267.44 | 324.55 | 301.03 | 234.54 | Upgrade |
Operating Income | 950.81 | 110.35 | 170.83 | 176.52 | 176.35 | Upgrade |
Interest Expense | -741.82 | -173.2 | -174.25 | -142.74 | -152.96 | Upgrade |
Interest & Investment Income | - | 1.32 | 1.09 | 3.52 | 1.49 | Upgrade |
Currency Exchange Gain (Loss) | - | -0 | -0.33 | 0.18 | 1.46 | Upgrade |
Other Non Operating Income (Expenses) | 246.97 | 100.35 | 11.15 | 3.91 | 19.27 | Upgrade |
EBT Excluding Unusual Items | 455.96 | 38.81 | 8.48 | 41.39 | 45.62 | Upgrade |
Gain (Loss) on Sale of Assets | - | 0.06 | - | - | - | Upgrade |
Other Unusual Items | - | 14.81 | - | - | - | Upgrade |
Pretax Income | 455.96 | 53.68 | 8.48 | 41.39 | 45.62 | Upgrade |
Income Tax Expense | 44.35 | 4.69 | 5.09 | 35.17 | 19.56 | Upgrade |
Earnings From Continuing Operations | 411.61 | 48.99 | 3.39 | 6.22 | 26.06 | Upgrade |
Minority Interest in Earnings | - | 0.05 | -0.64 | 0.63 | - | Upgrade |
Net Income | 411.61 | 49.04 | 2.75 | 6.85 | 26.06 | Upgrade |
Net Income to Common | 411.61 | 49.04 | 2.75 | 6.85 | 26.06 | Upgrade |
Net Income Growth | 739.30% | 1686.59% | -59.93% | -73.71% | -28.51% | Upgrade |
Shares Outstanding (Basic) | 28 | 28 | 28 | 28 | 28 | Upgrade |
Shares Outstanding (Diluted) | 28 | 28 | 28 | 28 | 28 | Upgrade |
EPS (Basic) | 14.71 | 1.75 | 0.10 | 0.24 | 0.93 | Upgrade |
EPS (Diluted) | 14.71 | 1.75 | 0.10 | 0.24 | 0.93 | Upgrade |
EPS Growth | 740.44% | 1684.19% | -59.93% | -73.68% | -28.46% | Upgrade |
Free Cash Flow | 1,358 | 651.28 | 269.68 | 422.97 | 140.2 | Upgrade |
Free Cash Flow Per Share | 48.51 | 23.27 | 9.64 | 15.11 | 5.01 | Upgrade |
Gross Margin | 31.68% | 22.13% | 17.08% | 18.79% | 15.48% | Upgrade |
Operating Margin | 9.24% | 6.46% | 5.89% | 6.94% | 6.64% | Upgrade |
Profit Margin | 4.00% | 2.87% | 0.10% | 0.27% | 0.98% | Upgrade |
Free Cash Flow Margin | 13.19% | 38.15% | 9.30% | 16.64% | 5.28% | Upgrade |
EBITDA | 1,422 | 184.81 | 241.51 | 225.12 | 221.95 | Upgrade |
EBITDA Margin | 13.81% | 10.83% | 8.33% | 8.86% | 8.36% | Upgrade |
D&A For EBITDA | 470.76 | 74.46 | 70.68 | 48.6 | 45.6 | Upgrade |
EBIT | 950.81 | 110.35 | 170.83 | 176.52 | 176.35 | Upgrade |
EBIT Margin | 9.24% | 6.46% | 5.89% | 6.94% | 6.64% | Upgrade |
Effective Tax Rate | 9.73% | 8.74% | 60.01% | 84.97% | 42.88% | Upgrade |
Revenue as Reported | 10,537 | 1,824 | 2,914 | 2,553 | 2,678 | Upgrade |
Advertising Expenses | - | - | - | 1.59 | 1.55 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.